In 2024, Xignite was acquired by QUODD, combining Xignite’s developer-first APIs with QUODD’s enterprise-grade market data services. Together, they offer over 500 APIs and global coverage across ...
SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. The unusually long REGAL trial timeline suggests GPS may be delivering a meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results